Երկիր: Ամերիկայի Միացյալ Նահանգներ
Լեզու: անգլերեն
Աղբյուրը: NLM (National Library of Medicine)
LORAZEPAM (UNII: O26FZP769L) (LORAZEPAM - UNII:O26FZP769L)
Mylan Pharmaceuticals Inc.
LORAZEPAM
LORAZEPAM 0.5 mg
ORAL
PRESCRIPTION DRUG
Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. Lorazepam tablets are contraindicated in patients with
Lorazepam Tablets, USP are available containing 0.5 mg, 1 mg or 2 mg of lorazepam, USP. The 0.5 mg tablets are white to off-white, round, unscored tablets debossed with M on one side of the tablet and 321 on the other side. They are available as follows: NDC 0378-2321-01 bottles of 100 tablets NDC 0378-2321-05 bottles of 500 tablets The 1 mg tablets are white to off-white, round, scored tablets debossed with MYLAN above the score and 457 below the score on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-2457-01 bottles of 100 tablets NDC 0378-2457-10 bottle of 1000 tablets The 2 mg tablets are white to off-white, round, scored tablets debossed with MYLAN above the score and 777 below the score on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-2777-01 bottles of 100 tablets NDC 0378-2777-05 bottles of 500 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. PHARMACIST: Dispense a Medication Guide with each prescription.
Abbreviated New Drug Application
Mylan Pharmaceuticals Inc. ---------- MEDICATION GUIDE Lorazepam Tablets, USP CIV (lor az' e pam) What is the most important information I should know about lorazepam tablets? • Lorazepam tablets are a benzodiazepine medicine. Taking benzodiazepines with opioid medicines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death. • Lorazepam tablets can make you sleepy or dizzy, and can slow your thinking and motor skills. o Do not drive, operate heavy machinery, or do other dangerous activities until you know how lorazepam tablets affect you. o Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking lorazepam tablets without first talking to your healthcare provider. When taken with alcohol or drugs that cause sleepiness or dizziness, lorazepam tablets may make your sleepiness or dizziness much worse. • Do not take more lorazepam tablets than prescribed. What are lorazepam tablets? • Lorazepam tablets are a prescription medicine used: o to treat anxiety disorders o for the short-term relief of the symptoms of anxiety or anxiety that can happen with symptoms of depression • Lorazepam tablets are a federal controlled substance (C-IV) because it can be abused or lead to dependence. Keep lorazepam tablets in a safe place to prevent misuse or abuse. Selling or giving away lorazepam tablets may harm others, and is against the law. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs. • It is not known if lorazepam tablets are safe and effective in children less than 12 years of age. • It is not known if lorazepam tablets are safe and effective for use for longer than 4 months. Do not take lorazepam tablets if you: • are allergic to lorazepam, other benzodiazepines, or any of the ingredients in lorazepam tablets. See the end of this Medication Guide for a complete list of ingredients in lorazepam tabl Կարդացեք ամբողջական փաստաթուղթը
LORAZEPAM- LORAZEPAM TABLET MYLAN PHARMACEUTICALS INC. ---------- WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death (see WARNINGS; PRECAUTIONS: Clinically Significant Interactions). • • • DESCRIPTION Lorazepam tablets, USP, an antianxiety agent, has the chemical formula, (±)-7-Chloro-5-(_o_- chlorophenyl)-1,3-dihydro-3-hydroxy-2_H_-1,4-benzodiazepin-2-one: C H C N O MW: 321.16 It is a white or almost white crystalline powder almost insoluble in water. Each lorazepam tablet, to be taken orally, contains 0.5 mg, 1 mg, or 2 mg of lorazepam, USP. The inactive ingredients present are lactose monohydrate, microcrystalline cellulose, polacrilin potassium and sodium stearyl fumarate. CLINICAL PHARMACOLOGY Studies in healthy volunteers show that in single high doses lorazepam tablets have a tranquilizing action on the central nervous system with no appreciable effect on the respiratory or cardiovascular systems. Lorazepam tablets are readily absorbed with an absolute bioavailability of 90 percent. Peak concentrations in plasma occur approximately 2 hours following administration. The peak plasma level of lorazepam from a 2 mg dose is approximately 20 ng/mL. The mean half-life of unconjugated lorazepam in human plasma is about 12 hours and for its major metabolite, lorazepam glucuronide, about 18 hours. At clinically relevant concentrations, lorazepam is Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. 15 10 L2 2 2 approximately 85% bound to plasma proteins. Lorazepam tablets are rapidly conjugated at its 3-hydroxy group into lorazepam glucuronide which is then excreted in the urine. Lorazepam glucuronide has no demonstrable CNS activity in animals. The plasma levels of lorazepam are proportional t Կարդացեք ամբողջական փաստաթուղթը